Page 153 - CW E-Magazine (4-2-2025)

Pharmaceuticals Pharmaceuticals

FUTURE PLANS EXPANDING PRESENCE
Glenmark Life Sciences renamed as Alivus Life Sciences Japan’s Takeda launches innovation centre

Glenmark Life Sciences has an- company invests more in the business, He did not divulge details for competitive in Bengaluru
nounced its change of identity to Alivus he said, “our approach will be to build reasons. In September 2023, Glenmark
Life Sciences, following its recent new levers to drive further growth.” Pharmaceuticals had agreed to divest Japan’s Takeda Pharmaceutical has care systems worldwide,” he
acquisition by Nirma, a diversifi ed con- The company expects to have its own 75 percent stake in Glenmark Life inaugurated its fi rst Innovation Capa- said. He added that the
glomerate with interest in consumer research and development facility, in Sciences to Nirma for Rs. 5,651-crore. bility Centre (ICC) in Bengaluru. This Bengaluru facility will focus on
products, chemicals, and pharmaceuti- about 18 months, he said, speaking to is the company’s fi rst ICC, a subset of developing products such as a
cals. analysts after the company announced Q3 performance the global capability centre (GCC), in plasma-derived therapies donor
its fi nancial performance for the third Alivus’ revenue from operations for the Asian region. management system and a
“The change is refl ective of the quarter (Q3) ended December 31, 2024. Q3FY25 was Rs. 641-crore, a growth global platform for healthcare
company’s evolving vision aimed at of 12 percent over the period last year; The ICC aims to employ 750 professional (HCP) data. “The
further strengthening its global pre- Responding to an analyst query on its Profi t After Tax (PAT) for the quarter professionals, including software engineers, Indian team will also develop
sence and a commitment to providing strategies that would continue or change under review stood at Rs. 137-crore, up data scientists, and cybersecurity experts, scalable, multi-language tools
innovative solutions in the API and in the company’s new avatar, Mr. Rawjee from Rs. 119-crore in the same period with a strong focus on artifi cial intelli- and other digital products to
CDMO space,” the company informed. said, in the past investments were last year. Performance in the quarter re- gence (AI)-driven talent, the company said Mr. Tilak Banerjee, Head of Takeda enhance patient support and
made largely in increasing capacities fl ected growth across both GPL (former said. ICC – India. care experiences,” he said.
Mr. Yasir Rawjee, Alivus Managing to service the business, with the excep- parent Glenmark Pharmaceuticals Ltd.)
Director and CEO, said the company tion of the oncology platform about and non-GPL segments, Mr. Rawjee While the Bengaluru facility will Takeda’s Chief Data and Technology Takeda already has a commercial
would continue with its strategy of two-and-a-half years ago. The company said. And geographically, regions like focus on research and development Offi cer, Mr. Gabriele Ricci, said the facility based in Gurgaon and has been
chasing high-value opportunities and is looking to build new platforms to India, Europe, the rest-of-the world (R&D) and digital health solutions, it company views AI as a key enabler in operational since 2003, apart from a
geographic diversification, besides fuel further growth, he said, adding markets and Japan contributed to the aims to become a digital biopharma- drug discovery, clinical trials, manu- partnership with Zydus – Zydus Take-
improving operational effi ciency. As the that some were ready to implement. growth, he added. ceutical company in the next 3-5 years. facturing, and patient care. “Emerging da Healthcare Pvt. Ltd. since 1999. In
“India was a natural choice for Takeda’s technologies like AI, generative AI, and the past few years, the company has
REGULATORY ACTION first ICC in Asia, and we chose robotics offer unique opportunities to also partnered with Sun Pharma, Cipla,
CDSCO fl ags 135 drugs as ‘not of standard quality’ Bengaluru specifi cally for the talent,” create solutions that can impact health- Lupin and Abbott India for certain drugs.

AMALGAMATION APPROVED
The Central Drugs Standard Con- Ministry note said identification of the drug products of the batch tested
trol Organisation has identifi ed select drug samples as NSQ is done based by the government laboratory. It CCI clears merger of nine pharma entities with
batches of 135-odd drugs and formu- on failure of the drug sample in one does not warrant any concerns on the
lations as ‘not of standard quality’ or the other specified quality para- other drug products available in the Sequent Scientifi c
(NSQ) for December 2024. meters. “The failure is specific to market,” a Ministry official said.
The Competition Commission of
Viyash is a pharmaceutical com-
Of the 135 drugs found to be not of Granules India’s Q3 net down 6% India (CII) has approved the proposed pany and through its subsidiaries is
standard quality, there were 51-odd that amalgamation of nine entities with primarily engaged in the development,
were identifi ed by Central drug labora- Hyderabad-based Granules India’s and pharmaceutical formulation pharmaceutical fi rm Sequent Scientifi c manufacture and sale of APIs and inter-
tories, the remaining 84 were fl agged net profit declined 6 percent at intermediates (PFI) contributed 76 Ltd. (SSL). “The proposed combination mediates for human healthcare in India.
by State drug testing labs. Typically, Rs. 117-crore in the third quarter percent, 12 percent and 12 percent involves a series of inter-connected
NSQ drugs are those that fail to meet ended December 2024 compared to of revenue from operations, res- steps carried out for the amalgama- Symed Labs, Appcure Labs, Vindhya
the quality standards or specifi cations. Rs. 125-crore in the corresponding pectively, in the third quarter. The tion of SRL, Viyash, Symed, Appcure, Pharma (India) and Vandana Life
quarter of previous financial year. company voluntarily paused the Vindhya Pharma, Vandana, Vindhya Sciences are wholly-owned subsidiaries
Some of the samples identified Revenues of the drugmaker too production at the Gagillapur plant Organics, Geninn and SV Labs with of Viyash while S V Labs is a wholly
include the thyroid medication Thy- decreased 2 percent at Rs. 1,137-crore in September last year for risk SSL as the ultimate surviving entity,” owned step-down subsidiary of Viyash.
rox 25 by Macleods Pharma, Okamet as against Rs. 1,150-crore in the same assessment on account of the US-FDA CCI said in a release.
tablets used to treat Type 2 diabetes period last year. observations. Subsequently, the pro- the animal health sector. Sequent The amalgamation will streamline
by Cipla, antibacterial medication duction resumed in October in a SSL offers active pharmaceutical Research Ltd. (SRL), a wholly-owned operations and strengthen SSL’s posi-
Ciprodac 500 tablets by Cadila, Finished dosages (FD), Active staggered manner, according to a ingredients (APIs), finished dosage subsidiary of SSL, is a contract tion in both the animal and human
among others. A Union Health Pharmaceuticals Ingredients (API) release. formulations, and analytical services for research organisation. healthcare segments.

152 Chemical Weekly February 4, 2025 Chemical Weekly February 4, 2025 153

Contents Index to Advertisers Index to Products Advertised